A Study of Volrustomig in People With Solid Tumor Cancer

Full Title

A Phase II, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination with Anti-cancer Agents in Participants with Advanced/Metastatic Solid Tumors

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Michael Offin’s office at 646-608-3763.

Protocol
26-273
Phase
Phase II (phase 2)
Disease Status
Newly Diagnosed
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT06535607